Constipation Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4470328
  • Report
  • 101 pages
  • P&S Market Research
1 of 4
The study analyzed that the constipation therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Most of the drugs in pipeline for the treatment of constipation are in late stage of development. Constipation is a common functional gastrointestinal (GI) disorder that is most prevalent in the elderly and female population. According to the journal Clinical Interventions in Aging, published in 2015, the prevalence of the disease is around 20% in the world population, varying between 2% and 27% in different countries. The economic impact of chronic constipation is significant in the U.S., with around 100,000 constipation-related hospitalizations annually.

Insights on Pipeline Segments:
Pharmaceutical companies are developing various drug candidates for the treatment of constipation in different stages of development including Filed, Phase III, Phase II, Phase I, and Pre-clinical. Albireo Pharma Inc. is in the process of developing a drug candidate, which is in the Filed stage of development, for treating constipation. There are small molecules as well as peptide type drug candidates in development for the treatment of constipation. A majority of the constipation therapeutics pipeline drugs are being developed as an oral dosage form.

Increasing prevalence of GI disorders boosting the growth of constipation pipeline

There has been considerable increase in the prevalence of GI disorders, such as non-alcoholic fatty liver disease, diabetes, pancreatitis, and acidity, in people. These problems have a huge impact on the digestion process, which, in turn, causes constipation. It has also been observed that synthetic foods too cause indigestion in people, which results in constipation. Thus, unhealthy dietary behavior too increases the chances of occurrence of constipation. Thus, increasing prevalence of GI disorders contributes as one of the key drivers for the development of drugs to treat constipation.

Technological advancements for the development of drug candidates to treat constipation

With advances in technology, many pharmaceutical companies are leveraging new and improved technologies for the development of drug candidates to treat constipation. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. They also allow development of specific targeted therapies with better drug delivery. For instance, Ardelyx Inc. has developed a unique platform that enables to discover targets in the GI tract, which control health and disease processes to optimize drug candidates and to understand their mechanisms of action.

Some of the players involved in the development of drug candidates for the treatment of constipation are Nordic Life Science Pipeline Inc., Enterin Inc., and Yuhan Corporation Ltd.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 by Industry Participant
2.2.2 by Company Type

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.1.1 Signs and Symptoms
4.1.2 Pathophysiology
4.1.3 Diagnosis
4.1.4 Treatment
4.1.5 Epidemiology
4.2 Key Drivers
4.8.1 Driver 1
4.8.2 Driver 2
4.3 Key Barrier
4.9.1 Barrier 1
4.4 Constipations Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

5. Constipation Therapeutics Pipeline Analysis by Phase (2017)
5.1 Filed
5.1.1 Elobixibat
5.1.1.1 Clinical trials
5.1.1.2 Clinical results
5.1.1.3 Strategic developments
5.2 Phase III
5.2.1 AJG 555
5.2.1.1 Clinical trials
5.2.1.2 Others
5.2.2 X
5.2.2.1 Clinical trials
5.2.3 X
5.2.3.1 Clinical trials
5.2.3.2 Clinical results
5.2.3.3 Others
5.2.3.4 Technology
5.3 Phase II
5.3.1 BLI 801
5.3.1.1 Clinical trials
5.3.2 X
5.3.2.1 Clinical trials
5.3.3 X
5.3.3.1 Clinical trials
5.3.4 X
5.3.4.1 Strategic developments
5.3.5 X
5.3.5.1 Clinical trials
5.3.5.2 Strategic developments
5.3.6 X
5.3.6.1 Clinical trials
5.3.7 X
5.3.7.1 Clinical trials
5.3.7.2 Clinical results
5.3.8 X
5.3.8.1 Clinical trials
5.3.8.2 Clinical results
5.3.9 X
5.3.9.1 Clinical trials
5.3.9.2 Technology
5.3.10 X
5.3.10.1 Clinical trials
5.3.10.2 Clinical results
5.3.10.3 Strategic developments
5.4 Phase I
5.4.1 NGM 282
5.4.1.1 Clinical trials
5.4.1.2 Strategic developments
5.4.1.3 Technology
5.4.2 X
5.4.2.1 Clinical trials
5.5 Pre-Clinical
5.5.1 X
5.5.1.1 Others
5.5.1.2 Technology
5.5.2 X

6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Constipation Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Constipation Therapeutics Pipeline

7. Competitive Landscape
7.1 Key Players Benchmarking for Constipation Therapeutics Pipeline
7.2 SWOT Analysis of Constipation Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Nordic Life Science Pipeline Inc.
8.1.1 Business Overview
8.1.2 Pipeline Products
8.2 Enterin Inc.
8.2.1 Business Overview
8.2.2 Pipeline Products
8.3 X
8.3.1 Business Overview
8.3.2 Pipeline Products
8.4 X
8.4.1 Business Overview
8.4.2 Pipeline Products
8.5 X
8.5.1 Business Overview
8.5.2 Pipeline Products
8.6 X
8.6.1 Business Overview
8.6.2 Pipeline Products
8.7 X
8.7.1 Business Overview
8.7.2 Pipeline Products
8.8 X
8.8.1 Business Overview
8.8.2 Pipeline Products
8.9 X
8.9.1 Business Overview
8.9.2 Pipeline Products

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 Pipeline Analysis of Constipation Therapeutics, by Company (2017)
Table 2 Description of Elobixibat
Table 3 Clinical Trials of Elobixibat
Table 4 Description of Ajg 555
Table 5 Clinical Trials of Ajg 555
Table 6 Description of X
Table 7 Clinical Trials of X
Table 8 Description of X
Table 9 Clinical Trials of X
Table 10 Description of Bli 801
Table 11 Clinical Trials of Bli 801
Table 12 Description of X
Table 13 Clinical Trials of X
Table 14 Description of X
Table 15 Clinical Trials of X
Table 16 Description of X
Table 17 Description of X
Table 18 Clinical Trials of X
Table 19 Description of X
Table 20 Clinical Trials of X
Table 21 Description of X
Table 22 Clinical Trials of X
Table 23 Description of X
Table 24 Clinical Trials of X
Table 25 Description of X
Table 26 Clinical Trials of X
Table 27 Description of X
Table 28 Clinical Trials of X
Table 29 Description of Ngm 282
Table 30 Clinical Trials of Ngm 282
Table 31 Description of X
Table 32 Clinical Trials of X
Table 33 Description of X
Table 34 Description of X
Table 35 Nordic Life Science Pipeline Inc. - at a Glance
Table 36 Enterin Inc. - at a Glance
Table 37 X - at a Glance
Table 38 X - at a Glance
Table 39 X - at a Glance
Table 40 X - at a Glance
Table 41 X - at a Glance
Table 42 X - at a Glance
Table 43 X - at a Glance

List of Figures
Fig 1 Research Methodology
Fig 2 Split of Primary And Secondary Research
Fig 3 Breakdown of Primary Research by Industry Participant
Fig 4 Breakdown of Primary Research by Company Type
Fig 5 Constipation Drug Candidates Under Development (2017)
Fig 6 Constipation Therapeutics Pipeline Split, by Molecule Type (2017)
Fig 7 Constipation Therapeutics Pipeline Split, by Route of Administration (2017)
Fig 8 Clinical Results Chart of X
Fig 9 Clinical Result of X
Fig 10 Breakdown of Clinical Trials, by Region
Fig 11 Breakdown of Clinical Trials, by Trial Status
Fig 12 Key Players Benchmarking
Fig 13 Swot Analysis
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Enterin Inc.
  • Nordic Life Science Pipeline
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll